Papillary renal neoplasm with reverse polarity is biologically and clinically distinct from eosinophilic papillary renal cell carcinoma
Pathology International · 2024-04 · 74 (4) · 222-226
DOI: 10.1111/pin.13417 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology International, online erschienen am 08.03.2024. Verfasst von Vincent Francis Castillo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ontario Institute for Cancer Research, Kidney Cancer Research Network of Canada (KCRNC), Kidney Cancer Canada (KCC).
Abstract (Originalsprache)
Papillary renal neoplasm with reverse polarity (PRNRP) is a recently described indolent entity with distinct features and its recognition from other oncocytic/eosinophilic papillary renal cell carcinoma (ePRCC) has important prognostic implications. ABCC2, a renal drug transporter, is overexpressed in aggressive PRCCs. In this study, we compared the clinicopathological parameters and the biological ABCC2 expression between PRNRP and ePRCC. PRNRP ( n = 8) and ePRCC ( n = 21) cases were selected from resection specimens and corresponding clinicopathological data were collected. ABCC2 immunohistochemical (IHC) staining was performed and ABCC2 staining patterns were classified as negative, cytoplasmic, and brush‐border. RNA in‐situ hybridization (ISH) was used to assess ABCC2 transcript levels. All eight PRNRP cases had weak cytoplasmic ABCC2 IHC reactivity; however, they showed no detectable ABCC2 transcripts on RNA ISH. In comparison, 76% (16/21) of ePRCCs showed ABCC2 IHC brush‐border expression and significantly higher ABCC2 RNA ISH transcript levels ( p < 0.001). Additionally, the ePRCC group showed a significantly larger tumor size ( p = 0.004), higher WHO/ISUP grade ( p < 0.001), and stage ( p = 0.044). None of the PRNRP cases showed disease progression, while 9.5% (2/21) ePRCCs had disease progression. PRNRP is clinically and biologically distinct from ePRCC. Hence, it is crucial to differentiate between these two entities, particularly in needle core biopsies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
- Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.
- Department of Pathology and Laboratory Medicine, Alberta Precision Laboratories and University of Calgary, Calgary, Alberta, Canada.
- Division of Pathology, University Health Network, Toronto, Ontario, Canada.
- Department of Laboratory Medicine, Unity Health Toronto, Toronto, Ontario, Canada.
Förderung
- Ontario Institute for Cancer Research
- Kidney Cancer Research Network of Canada (KCRNC)
- Kidney Cancer Canada (KCC)
- Canadian Urological Association Scholarship Fund (CUASF)
Zitieren
APA
Castillo, V. F., Trpkov, K., Van der Kwast, T., Rotondo, F., Hamdani, M., & Saleeb, R. (2024). Papillary renal neoplasm with reverse polarity is biologically and clinically distinct from eosinophilic papillary renal cell carcinoma. Pathology International, 74(4), 222-226. https://doi.org/10.1111/pin.13417
Vancouver
Castillo VF, Trpkov K, Van der Kwast T, Rotondo F, Hamdani M, Saleeb R. Papillary renal neoplasm with reverse polarity is biologically and clinically distinct from eosinophilic papillary renal cell carcinoma. Pathology International. 2024;74(4):222-226. doi:10.1111/pin.13417
BibTeX
@article{Castillo2024,
author = {Castillo, Vincent Francis and Trpkov, Kiril and Van der Kwast, Theodorus and Rotondo, Fabio and Hamdani, Malek and Saleeb, Rola},
title = {Papillary renal neoplasm with reverse polarity is biologically and clinically distinct from eosinophilic papillary renal cell carcinoma},
journal = {Pathology International},
year = {2024},
volume = {74},
number = {4},
pages = {222--226},
doi = {10.1111/pin.13417}
}
EUVIMED